PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

By Insights from 2023 ESMO Annual Meeting FEATURING Nicolas Girard

829 views

November 17, 2023

Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.

Comments 0